Proceeds from the financing will be used to advance Vedanta’s clinical portfolio including a Phase 1/2 study of VE416 in food allergy, a Phase 1b/2 study of VE800 and OPDIVO (nivolumab) in advanced or metastatic cancers, and the ongoing Phase 2 study of VE303 in recurrent